Your Support & How It Was Used
Fiscal Year 2024 Impact Report
(July 1, 2023 – June 30, 2024)
Get the 2024 Impact Report Now
Financial Scale
Investing in Cancer Immunotherapy Research
CRI’s research is guided by our renowned Scientific Advisory Council, led by 2018 Nobel laureate James P. Allison, PhD. CRI scientists around the world are leading the charge to fuel the next wave of immunotherapy treatments.
$22.8M
Invested in research
64
Grants
42
Institutions
7
Countries
Take a glimpse at CRI’s inaugural Bioinformatics Bootcamp, created to equip immunologists with essential data science skills. Forty-four CRI Postdoctoral Fellows gained hands-on training to leverage data and advance cancer immunotherapy research.
“Immunotherapy is one of the most significant advances for treating cancer in the modern era. The field is what it is today because CRI continues to be laser-focused on breakthrough immunotherapy research.”
James P. Allison, PhD
The University of Texas MD Anderson Cancer Center
CRI Scientific Advisory Council Director
2018 Nobel Laureate
Make your impact on cancer research
*Includes 3 Fellowships to Promote Racial Diversity and 4 Immuno-Informatics Fellowships
Program Scale
Building a Community of Scientific Talent
CRI is committed to building a community of scientific talent by supporting outstanding researchers across diverse disciplines. Our investment in fellowships, awards, and integration programs ensures that scientists are empowered to take risks, innovate, and bridge the gap between research and clinical practice.
Discover the latest in our Fiscal Year 2024 Impact Video Series, featuring CRI Postdoctoral Fellow Dr. Chiara Falcomatà’s pioneering research on pancreatic cancer’s evasion of the immune system. CRI’s 71 years of investment in research are transforming treatment possibilities, with 45% of newly diagnosed cancer patients now eligible for immunotherapy.
Gavin Peter Dunn, MD, PhD
Massachusetts General Hospital
CRI Lloyd J. Old STAR
Gavin Peter Dunn, MD, PhD, is a neurosurgeon-scientist studying how the immune system responds to brain tumors, a largely uncharted area of cancer research. While immunotherapies have revolutionized treatment for certain cancers, they have yet to make a significant impact on brain tumors, partly due to the complex biology and unique barriers present in the brain. Recently, Dr. Dunn made a groundbreaking discovery, identifying a subset of immune cells that behave differently in brain tumors—a finding that could be leveraged for developing new therapies.
Chiara Falcomatà, PhD
Icahn School of Medicine at Mount Sinai
CRI Postdoctoral Fellow
Pancreatic cancer is one of the most aggressive and deadly forms of cancer, with a grim prognosis and few effective treatment options. Its tumor environment cleverly evades the body’s immune response, rendering many therapies ineffective—a challenge scientists are still working to fully understand. Chiara Falcomatà, PhD, is at the forefront of research aimed at uncovering how pancreatic cancer cells outmaneuver the immune system.
CRI Lloyd J. Old STAR Gavin Peter Dunn, MD, PhD, a neurosurgeon-scientist, is studying how the immune system responds to brain tumors. With the support and funding from CRI, Dr. Dunn is tackling this largely unexplored area of cancer research from multiple angles, paving the way for potential new treatments.
Our Mission
SAVE MORE LIVES by fueling the discovery and development of powerful immunotherapies for all cancers.
Human Scale
Bringing the Promise of Immunotherapy to More Patients
CRI is committed to bringing the promise of immunotherapy to more patients worldwide. With 29 cancers now treatable with immunotherapy, new FDA approvals, and nearly half of all newly diagnosed patients eligible, CRI’s impact is transforming lives on a global scale.
29
Cancers now treatable with immunotherapy
45%
Of newly diagnosed patients are eligible for immunotherapy
13
New FDA approvals
Karen was diagnosed with stage 1 triple-negative breast cancer. After undergoing traditional treatments, her cancer returned in 2017 as metastatic, accompanied by a devastating prognosis of just 18 to 24 months to live. Refusing to accept this, Karen sought information about immunotherapy and other treatment options and discovered CRI. She found a phase 1 clinical trial that offered new hope.
Trust and Transparency
Investing in Impact
In FY2024, 83% of CRI’s total operating expenses went directly to supporting research and education programs. CRI consistently receives exemplary marks from watchdog groups, including an A Rating from CharityWatch, Platinum Seal of Transparency from GuideStar, and a 100% Four Stars rating from Charity Navigator. CRI is a proud member of the BBB Wise Giving Alliance, meeting all 20 standards of charity accountability.
Make your impact on cancer research
Ranked among the top 5% of U.S. rated charities
